Biotech · Private company · San Carlos, CA, US

Glytr Therapeutics, Inc.

Track this companyFree. Adds Glytr Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials0None registered

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

NIH awards4

Maximizing GlyTR pan-cancer immunotherapy by enhancing target densityFiscal year 2026 · $1MNIH RePORTER 4R42CA302415-02 · fetched Nov 12, 2026
Maximizing GlyTR pan-cancer immunotherapy by enhancing target densityFiscal year 2025 · $463.5KNIH RePORTER 1R42CA302415-01A1 · fetched Nov 12, 2026
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyFiscal year 2025 · $1.1MNIH RePORTER 5R42CA285234-03 · fetched Nov 12, 2026
Extended half-life GlyTR1 combined with checkpoint blockade for Cancer ImmunotherapyFiscal year 2024 · $908.9KNIH RePORTER 4R42CA285234-02 · fetched Nov 12, 2026